Clinical studies and trials have shown that patients with dMMR/MSI-H CRC and pMMR/MSI-L or MSS CRC respond inconsistently to anti-PD-1/PD-L1 mAbs, which is associated with differences in the components of TIME. This evidence concerns the gene CD274 and colorectal carcinoma.